These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35330381)

  • 1. Feasibility of Adjuvant Treatment with Abemaciclib-Real-World Data from a Large German Breast Center.
    Dannehl D; Volmer LL; Weiss M; Matovina S; Grischke EM; Oberlechner E; Seller A; Walter CB; Hahn M; Engler T; Brucker SY; Hartkopf AD
    J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry.
    Frevert ML; Dannehl D; Jansen L; Hermann S; Schäffler H; Huwer S; Janni W; Juhasz-Böss I; Hartkopf AD; Taran FA
    Arch Gynecol Obstet; 2024 Jun; 309(6):2811-2819. PubMed ID: 38472501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
    Paluch-Shimon S; Neven P; Huober J; Cicin I; Goetz MP; Shimizu C; Huang CS; Lueck HJ; Beith J; Tokunaga E; Contreras JR; de Sant'Ana RO; Wei R; Shahir A; Nabinger SC; Forrester T; Johnston SRD; Harbeck N
    Ther Adv Med Oncol; 2023; 15():17588359231151840. PubMed ID: 36756142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors.
    Kanjanapan Y; Anderson W; Smith M; Green J; Chalker E; Craft P
    Clin Breast Cancer; 2024 Aug; ():. PubMed ID: 39294027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
    Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
    Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
    Martín M; Carrasco E; Rodríguez-Lescure Á; Andrés R; Servitja S; Antón A; Ruiz-Borrego M; Bermejo B; Guerrero Á; Ramos M; Santaballa A; Muñoz M; Cruz J; Lopez-Tarruella S; Chacón JI; Álvarez I; Martínez P; Miralles JJ; Polonio Ó; Jara C; Aguiar-Bujanda D
    Breast Cancer Res Treat; 2023 Sep; 201(2):151-159. PubMed ID: 37338729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world data on patients with early breast cancer who were prescribed abemaciclib adjuvant therapy in Japan.
    Shimoi T; Pathadka S; Sekine N; Cai Z; Tanizawa Y; Kawaguchi T; Saji S; Yamashita T
    Future Oncol; 2024; 20(29):2179-2188. PubMed ID: 38861285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world experience of abemaciclib for adjuvant and metastatic breast cancer.
    Drowne T; Armgardt E; Svoboda A
    J Oncol Pharm Pract; 2024 Aug; ():10781552241279189. PubMed ID: 39196656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers.
    Schäffler H; Mergel F; Pfister K; Lukac S; Fink A; Veselinovic K; Rack B; Fink V; Leinert E; Dimpfl M; Englisch A; Tegeler CM; Seller A; Grischke EM; Hahn M; Volmer LL; Engler T; Frevert ML; Taran FA; Janni W; Brucker SY; Hartkopf AD; Dannehl D
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of abemaciclib in primary breast cancer: a narrative review of MonarchE.
    Takahashi N; Shimizu C; Shimomura A; Toi M
    Transl Breast Cancer Res; 2022; 3():3. PubMed ID: 38751527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy.
    Davie A; Traoré S; Giovannitti M; Pompilio G; Lambton M; Cakar E; Chatterjee A
    Glob Reg Health Technol Assess; 2023; 10():62-69. PubMed ID: 37811343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
    Tolaney SM; Guarneri V; Seo JH; Cruz J; Abreu MH; Takahashi M; Barrios C; McIntyre K; Wei R; Munoz M; Antonio BS; Liepa AM; Martin M; Johnston SRD; Kellokumpu-Lehtinen PL; Harbeck N
    Eur J Cancer; 2024 Mar; 199():113555. PubMed ID: 38244363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2- Early Breast Cancer.
    Raheem F; Ofori H; Simpson L; Shah V
    Ann Pharmacother; 2022 Feb; ():10600280211073322. PubMed ID: 35135362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Less necessity of adjuvant S-1 treatment in non-monarchE-eligible patients.
    Yu M; Takada M; Yamada H; Fujimoto H; Sakakibara J; Yamamoto H; Nagashima T; Ohtsuka M
    Cancer Med; 2023 Jun; 12(12):13193-13203. PubMed ID: 37162105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.
    Toi M; Boyle F; Im YH; Reinisch M; Molthrop D; Jiang Z; Wei R; Sapunar F; Grimes BR; Nabinger SC; Johnston SRD
    Oncologist; 2023 Jan; 28(1):e77-e81. PubMed ID: 36342342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients' Needs?
    Jongbloed EM; Blommestein HM; van Schoubroeck HM; Martens JWM; Wilting SM; Uyl-de Groot CA; Jager A
    Breast Cancer (Dove Med Press); 2023; 15():147-161. PubMed ID: 36814469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer.
    Cuyun Carter G; Sheffield KM; Gossai A; Huang YJ; Zhu YE; Bowman L; Nash Smyth E; Mathur R; Cohen AB; Rasmussen E; Balakrishna S; Morato Guimaraes C; Rybowski S; Seidman AD
    Curr Med Res Opin; 2021 Jul; 37(7):1179-1187. PubMed ID: 33970738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abemaciclib Therapy Using the MonarchE Criteria Results in Large Numbers of Excess Axillary Node Clearances-Time to Pause and Reflect?
    Ahari D; Wilkinson M; Ali N; Taxiarchi VP; Dave RV; Gandhi A
    Cancers (Basel); 2024 Sep; 16(17):. PubMed ID: 39272930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force.
    Faragalla H; Plotkin A; Barnes P; Lu FI; Kos Z; Mulligan AM; Bane A; Nofech Mozes S
    Curr Oncol; 2023 Mar; 30(3):3079-3090. PubMed ID: 36975446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer-Real-World Data from Two Large German Breast Centers.
    Dannehl D; Engler T; Volmer LL; Tegeler CM; Fusshoeller J; Gabrysch E; Eissler K; Seller A; Grischke EM; Hahn M; Gruber I; Schochter F; Pfister K; Veselinovic K; Leinert E; Rack B; Fink V; Janni W; Brucker SY; Hartkopf AD; Schäffler H
    Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.